Researchers are zeroing in on a surprising culprit behind multiple sclerosis (MS): the Epstein-Barr virus (EBV). Long known for causing mononucleosis (“mono”), EBV is now strongly suspected of also triggering MS, an autoimmune disorder that attacks the nerves and can lead to symptoms like numbness, muscle weakness, and vision problems. Over the last few years, scientists have built a compelling case that almost everyone who develops MS was exposed to EBV first, suggesting that fighting this common virus could be the key to better, more targeted MS therapies.
The EBV–MS Connection
Evidence linking EBV and MS is now so convincing that some researchers believe EBV infection is a “necessary trigger” for the disease. People who’ve never had EBV are at near-zero risk for MS. Yet simply being exposed to EBV isn’t the whole story—scientists think specific processes, like “molecular mimicry” (where the virus tricks the immune system into attacking healthy tissue) and “immune dysregulation” (where EBV changes how the body defends itself), are at play. A third theory, the “driver hypothesis,” suggests EBV keeps MS active by cycling between silent (latent) and active (lytic) forms, continually presenting immune cells with viral signals that ignite ongoing inflammation and nerve damage.
Clues from HIV-Positive Patients
Surprisingly, people living with HIV—who often take powerful antiretroviral drugs—are less likely to get MS, especially when their treatment includes drugs that fight EBV. Big data studies from England, Denmark, and Sweden show a clear trend: HIV-positive people benefit from antiretroviral therapy not only in reducing their risk of HIV complications but also MS. This provides strong support for exploring such drugs in the prevention and treatment of MS even in HIV-negative patients.
Rethinking MS Treatments: Could Current Drugs Work by Targeting EBV?
Modern MS therapies, especially those that deplete B cells (a type of immune cell key to both EBV infection and MS), may already be working by reducing the push and pull of EBV in the nervous system. Researchers say it’s time to revisit how these drugs actually help patients, and whether their anti-EBV effects explain their success. There’s growing momentum for more direct approaches, including:
- New antiviral drugs that penetrate the central nervous system (CNS) to reach EBV wherever it hides.
- Immunotherapies, like EBV vaccines or engineered T cells, that could “teach” the body to better control the virus.
- Higher-dose B-cell depleting medications aimed specifically at B cells in the brain and spinal cord.
Challenges & Next Steps
Despite encouraging breakthroughs, many hurdles remain. EBV infection is almost universal, and MS can develop years—even decades—after the original exposure. This makes it hard for scientists to run long, meaningful studies following EBV-negative people over time to see if and how they develop MS. Additionally, a number of attempts at EBV-targeted therapy, like the much-watched EMBOLD trial for the drug ATA188, haven’t succeeded yet.
Researchers recommended several new strategies to finally prove the EBV–MS link and create effective treatments:
- Large-scale, long-term studies tracking people before and after EBV infection, monitoring how their immune health changes.
- Investigating how different forms of EBV infection (like infectious mononucleosis) interact with the nervous system.
- Re-evaluating the mechanisms of existing and experimental drugs to better understand their impact on EBV biology and MS.
The Future: EBV as a Therapeutic Target
If EBV is confirmed as the main driver of MS, future treatments could be more proactive, starting before symptoms begin or targeting the virus at multiple stages. Options could range from “CNS-penetrant” antivirals to vaccines or cell-based immunotherapies designed to restore immunity or block viral triggers. The hope is that by neutralizing EBV’s impact, doctors might halt, reduce, or even prevent the nerve damage that defines MS.
What Does This Mean for Patients?
For millions affected by MS or at risk, these advances offer cautious optimism. Current treatments may soon be joined by a new crop of therapies aimed not just at controlling inflammation, but at eliminating or taming a hidden viral threat. While it may take years for EBV-targeted drugs and vaccines to reach the market, research is moving forward rapidly—and the path to preventing or reversing MS may be closer than ever before.
